Sirion Therapeutics Inc. April 26 announced that Zirgan (ganciclovir ophthalmic gel) now is commercially available.
Zirgan is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis, an ocular disease caused by the herpes simplex virus, the Tampa, Fla.-based company said.
The Food and Drug Administration approved Zirgan in September 2009 (7 PLIR 1084, 9/18/09).
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.